Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Common Stock Repurchased

Cash spent buying back the company's own shares.

Novartis AGNYSE: NVS

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased declines year over year

Q2 FY2026 common stock repurchased of $1.2B (cash outflow) fell 55.9% year over year, behind the -38.0% change in trailing-twelve-month common stock repurchased. Sequentially, it fell 36.1% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.

Context

  • Common stock repurchased amounted to 16.9% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Common stock repurchased grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -55.9% toward the trailing-twelve-month pace of -38.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.2B-36.1% QoQ
Last fiscal yearDec 2025
-$9.26B+11.1% YoY
LTMJun 2026
-$6.85B-38.0% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.9%——
1 year+11.1%——
3-year CAGR-4.6%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(9.26B) USD
Year-over-year change
-11.1%

Common Stock Repurchased vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -38.0% is the 7th highest of 8, against a peer median of +22.2%.
  • Common stock repurchased amounts to 12.3% of revenue for NVS, versus a peer median of 2.4%.
NVS Competitors
Common Stock Repurchased for NVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$7.88B USD+82.8%-0.5%7.9%
NVSNovartis AGLTM Jun 2026$6.85B USD-38.0%-4.6%12.3%
NVONovo Nordisk A/SLTM Jun 2026DKK 5.9B DKK-47.7%-61.4%1.8%
MRKMerck & Co., Inc.LTM Jun 2026$4.21B USD+22.2%—6.3%
ABBVAbbVie Inc.LTM Jun 2026$1.51B USD+11.6%-13.0%2.3%
GILDGilead Sciences, Inc.LTM Jun 2026$1.44B USD-24.5%+11.2%4.7%
SNYSanofiLTM Jun 2026€1.21B EUR—+125.2%2.5%
GSKGSK plcLTM Jun 2026£1.08B GBP+34.0%—3.3%
AZNAstraZeneca PLCLTM Sep 2026$348.8M USD+2624.7%—0.6%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$98M USD——0.2%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding NVS) —+22.2%-0.5%2.4%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income22.91B6.05B8.57B11.94B14.06B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
Deferred Income Tax1.63B1.13B551M1.7B(361.84M)
Stock-Based Compensation700M791M865M1.04B0
Change in Working Capital(73M)(796M)(369M)(706M)(3.08B)
Accounts Receivables(352M)(397M)(1.5B)(931M)(1.13B)
Inventory(102M)(560M)(546M)(225M)34.17M
Accounts Payables(111M)(181M)479M(105M)(274.4M)
Other Working Capital492M342M1.2B555M(1.71B)
Other Non-Cash Items(15.68B)359M(3.44B)(2.43B)3.27B
Operating Cash Flow15.07B14.24B14.46B17.62B19.24B
Capital Expenditures(2.56B)(2.24B)(2.75B)(3.81B)(1.56B)
Acquisitions (Net)20.46B(864M)(3.57B)(3.83B)(3.01B)
Purchases of Investments(16.59B)(34.81B)(747M)(3.65B)(304.55M)
Sales of Investments2.74B39.49B11.6B3.7B2.19B
Other Investing Activities(1.34B)(1.43B)(624M)(2.38B)140.72M
Investing Cash Flow4.21B1.47B5.6B(7.51B)(4.9B)
Debt Repayment(5.67B)(2.59B)(1.94B)4.39B2.72B
Common Stock Issued000027.14M
Common Stock Repurchased(3.06B)(10.65B)(8.72B)(8.33B)(9.26B)
Dividends Paid(7.37B)(7.51B)(7.26B)(7.62B)(7.86B)
Other Financing Activities(169M)181M3.63B(177M)(577.95M)
Financing Cash Flow(16.26B)(20.56B)(14.28B)(11.74B)(14.94B)
Effect of Forex Changes(266M)(32M)100M(298M)579.07M
Net Change in Cash2.75B(4.89B)5.88B(1.93B)(24M)
Free Cash Flow12.52B12B11.71B13.81B17.69B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.